Abstract:Development of novel therapeutic strategies that reactivate latent HIV and sensitize reactivated cells to apoptosis is crucial towards elimination of the latent viral reservoir. Among the clinically relevant latency reversing agents (LRA) under investigation, the γ c-cytokine IL-15 and the superagonist N-803 have been shown to reactivate latent HIV ex vivo and in vivo . However, their clinical benefit can be hindered by IL-15 promoting survival of infected cells. We previously identified a small molecule, HODHBt, that sensitizes latently infected cells to death upon reactivation with γ c-cytokines through a STAT-dependent pathway. In here, we aimed to identify and evaluate FDA-approved compounds that could also sensitize HIV-infected cells to apoptosis. Using the Connectivity Map (CMap), we identified the retinol derivative 13- cis -retinoic acid (Isotretinoin) causes similar transcriptional changes as HODHBt. Isotretinoin enhances IL-15-mediated latency reversal without inducing proliferation of memory CD4 T cells. Ex vivo analysis of PBMCs from ACTG A5325, where Isotretinoin was administered to ART-suppressed people with HIV, showed that Isotretinoin treatment enhances IL-15-mediated latency reversal. Furthermore, we showed that a combination of IL-15 with Isotretinoin promotes the reduction of translation-competent reservoirs ex vivo . Mechanistically, combination of IL-15 and Isotretinoin increases caspase-3 activation specifically in HIV-infected cells but not uninfected cells. Our results suggest that Isotretinoin can be a novel approach to target and eliminate translation-competent HIV reservoirs. Even with the development and rapid advancement of antiretroviral therapies (ART) against HIV in the past three decades, there is still no generalized cure for HIV. Identification of novel therapeutic interventions that target the latent reservoir could provide new avenues to find a cure. In this work, we evaluated the ability of the FDA-approved compound Isotretinoin to reactivate latent HIV and promote a reduction of the latent reservoir ex vivo . Our studies found that Isotretinoin can enhance the ability of IL-15 to reactivate latent reservoirs. Furthermore, using samples from clinical trial ACTG A5325 (NCT01969058) we show that Isotretinoin sensitizes latent HIV to reactivation by IL-15. Finally, we demonstrate that Isotretinoin can sensitize reactivated cells to death via apoptosis. Overall, this study demonstrate that Isotretinoin could be used in combinatorial strategies towards the development of an HIV cure to promote reduction of latent reservoirs.

A Synthetic Retinoid Antagonist Inhibits the Human Immunodeficiency Virus Type 1 Promoter.

RbAp48, a Novel Inhibitory Factor That Regulates the Transcription of Human Immunodeficiency Virus Type 1.

Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency

Role of the Retinoic Acid Receptor-Α in HIV-associated Nephropathy

SAMHD1:a new HIV-1 inhibitory factor

Retinoic acid enhances HIV-1 reverse transcription and transcription in macrophages via mTOR-modulated mechanisms

Inhibition of the TRIM24 bromodomain reactivates latent HIV-1

Isotretinoin promotes elimination of translation-competent HIV latent reservoirs in CD4T cells

Pharmacological Activation of the Circadian Component REV-ERB Inhibits HIV-1 Replication.

HIV-1 Downregulates the Expression and Phosphorylation of Receptor Tyrosine Kinase by Targeting the NF-κB Pathway

Retinoic Acid-induced Transcriptional Modulation of the Human Interferon-γ Promoter

Human Immunodeficiency Virus (HIV)-1 Tat Downregulates the Phosphorylation of Recepteur D'origine Nantais (RON) Receptor Tyrosine Kinase Induced by Macrophage-Stimulating Protein

The receptor tyrosine kinase RON represses HIV-1 transcription by targeting RNA polymerase II processivity.

Retroviral Restriction Factors Trim5 Alpha: Therapeutic Strategy To Inhibit Hiv-1 Replication

Ripretinib inhibits HIV-1 transcription through modulation of PI3K-AKT-mTOR

Transcriptional Suppression of the Human T-Cell Leukemia Virus Type I Long Terminal Repeat Occurs by an Unconventional Interaction of a CREB Factor with the R Region

Evaluation of the Innate Immune Modulator Acitretin as a Strategy To Clear the HIV Reservoir

The CREB Regulated Transcription Coactivator 2 Suppresses HIV-1 Transcription by Preventing RNA Pol II from Binding to HIV-1 LTR.

Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing

Selective Small Molecules Blocking HIV-1 Tat and Coactivator PCAF Association.

Retinoblastoma Binding Protein 4 Represses HIV-1 Long Terminal Repeat-Mediated Transcription by Recruiting NR2F1 and Histone Deacetylase.